Spanish ostoeoporosis vastly under-diagnosed “due to lack of bone densitometry”
This article was originally published in Clinica
Executive Summary
Poor access to bone densitometry is the main reason why less than one in five of people with ostoeoporosis in Spain are aware of their condition. The problem is exacerbated by low rates of preventive screening.
You may also be interested in...
Market Intel: Expanding Elderly Population Gives Leg Up To Osteoporosis Dx Growth
The global market for osteoporosis diagnostic products is expected to expand from $253m in 2015 to $304m by 2020, fueled by a rising aging population and the need to test for osteoporosis and associated fracture risk. This article offers an in-depth look at the growth markets for both bone densitometer testing and biochemical marker tests, as well as the evolving competitive landscape, and the drivers and barriers to market entry.
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.